Holocene Advisors LP Has $192.88 Million Position in Cencora, Inc. $COR

Holocene Advisors LP increased its position in shares of Cencora, Inc. (NYSE:COR) by 59.2% in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 643,238 shares of the company’s stock after buying an additional 239,142 shares during the quarter. Holocene Advisors LP owned 0.33% of Cencora worth $192,875,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of the company. ICONIQ Capital LLC acquired a new stake in shares of Cencora in the second quarter valued at approximately $207,000. Engineers Gate Manager LP acquired a new position in Cencora during the second quarter worth $6,841,000. Benjamin Edwards Inc. grew its position in Cencora by 6.5% in the second quarter. Benjamin Edwards Inc. now owns 9,455 shares of the company’s stock valued at $2,835,000 after purchasing an additional 576 shares in the last quarter. BI Asset Management Fondsmaeglerselskab A S increased its stake in Cencora by 31.2% in the 2nd quarter. BI Asset Management Fondsmaeglerselskab A S now owns 122,354 shares of the company’s stock valued at $36,688,000 after buying an additional 29,071 shares during the last quarter. Finally, Brevan Howard Capital Management LP increased its stake in Cencora by 555.9% in the 2nd quarter. Brevan Howard Capital Management LP now owns 32,364 shares of the company’s stock valued at $9,704,000 after buying an additional 27,430 shares during the last quarter. Institutional investors own 97.52% of the company’s stock.

Cencora Stock Up 0.4%

COR opened at $345.86 on Friday. The stock’s fifty day simple moving average is $343.29 and its 200 day simple moving average is $311.20. Cencora, Inc. has a 1-year low of $223.92 and a 1-year high of $377.54. The stock has a market cap of $67.09 billion, a PE ratio of 43.50, a price-to-earnings-growth ratio of 1.63 and a beta of 0.63. The company has a current ratio of 0.90, a quick ratio of 0.55 and a debt-to-equity ratio of 4.32.

Cencora (NYSE:COR) last released its quarterly earnings data on Wednesday, November 5th. The company reported $3.84 EPS for the quarter, beating the consensus estimate of $3.79 by $0.05. The firm had revenue of $83.73 billion for the quarter, compared to the consensus estimate of $83.36 billion. Cencora had a net margin of 0.48% and a return on equity of 227.15%. The company’s quarterly revenue was up 5.9% on a year-over-year basis. During the same period in the previous year, the company earned $3.34 earnings per share. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. As a group, research analysts expect that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, December 1st. Shareholders of record on Friday, November 14th were issued a $0.60 dividend. The ex-dividend date of this dividend was Friday, November 14th. This represents a $2.40 annualized dividend and a yield of 0.7%. This is an increase from Cencora’s previous quarterly dividend of $0.55. Cencora’s payout ratio is currently 30.19%.

Insider Activity at Cencora

In related news, CEO Robert P. Mauch sold 5,096 shares of the business’s stock in a transaction on Tuesday, November 18th. The stock was sold at an average price of $366.64, for a total value of $1,868,397.44. Following the completion of the sale, the chief executive officer directly owned 65,746 shares in the company, valued at $24,105,113.44. The trade was a 7.19% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Chairman Steven H. Collis sold 31,350 shares of the stock in a transaction on Tuesday, September 16th. The stock was sold at an average price of $289.86, for a total value of $9,087,111.00. Following the transaction, the chairman owned 305,913 shares in the company, valued at $88,671,942.18. The trade was a 9.30% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 46,640 shares of company stock valued at $14,099,338 over the last 90 days. Company insiders own 10.80% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently weighed in on COR shares. TD Cowen raised their price objective on Cencora from $350.00 to $400.00 and gave the company a “buy” rating in a report on Monday, November 10th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Cencora in a research report on Monday. Mizuho increased their price objective on Cencora from $340.00 to $380.00 and gave the company an “outperform” rating in a report on Thursday, November 6th. Wells Fargo & Company raised their target price on shares of Cencora from $354.00 to $405.00 and gave the company an “overweight” rating in a research note on Tuesday, November 11th. Finally, Wall Street Zen lowered shares of Cencora from a “buy” rating to a “hold” rating in a research report on Friday, November 28th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, Cencora presently has an average rating of “Moderate Buy” and an average target price of $373.50.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.